MBMartina Monika Bosch

Martina Monika Bosch

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Martina Monika Bosch has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • High Altitude Retinal Hemorrhages–An Update

    by Martina M. Bosch, Daniel Barthelmes, Klara Landau

    Bosch, Martina M., Daniel Barthelmes, and Klara Landau. High altitude retinal hemorrhages: an update. High Alt Med Biol. 13:240–244, 2012. —Retinal hemorrhages represent a common phenomenon in eyes of high altitude climbers. In this review, we present an update about this entity, with focus on its pathophysiology and practical implications. Due to their delayed appearance in the course of an expedition, retinal hemorrhages are not predictive when assessing the risk for life-threatening complications related to hypobaric hypoxia. Consequences for ocular health depend greatly on the extent and localization of retinal bleedings, but are generally mild and reversible in healthy eyes.


  • Open Access

    Delayed Appearance of High Altitude Retinal Hemorrhages

    by Daniel Barthelmes, Martina M. Bosch, Tobias M. Merz, Benno L. Petrig, Frederic Truffer, Konrad E. Bloch, Timothy A. Holmes, Philippe Cattin, Urs Hefti, Miriam Sellner, et al.

    Retinal hemorrhages have been described as a component of high altitude retinopathy (HAR) in association with altitude illness. In this prospective high altitude study, we aimed to gain new insights into the pathophysiology of HAR and explored whether HAR could be a valid early indicator of altitude illness. 28 mountaineers were randomly assigned to two ascent profiles during a research expedition to Mt. Muztagh Ata (7546 m/24,751 ft). Digital fundus photographs were taken prior to expedition at 490 m (1,607 ft), during expedition at 4497 m (14,750 ft = base camp), 5533 m (18,148 ft), 6265 m (20,549 ft), 6865 m (22,517 ft) and 4.5 months thereafter at 490 m. Number, size and time of occurrence of hemorrhages were recorded. Oxygen saturation (SpO2) and hematocrit were also assessed. 79% of all climbers exhibited retinal hemorrhages during the expedition. Number and area of retinal bleeding increased moderately to medium altitudes (6265 m). Most retinal hemorrhages were detected after return to base camp from a high altitude. No post-expeditional ophthalmic sequelae were detected. Significant negative (SpO2 Beta: −0.4, p<0.001) and positive (hematocrit Beta: 0.2, p = 0.002, time at altitude Beta: 0.33, p = 0.003) correlations with hemorrhages were found. When closely examined, a very large amount of climbers exhibit retinal hemorrhages during exposure to high altitudes. The incidence of retinal hemorrhages may be greater than previously appreciated as a definite time lag was observed between highest altitude reached and development of retinal bleeding. Retinal hemorrhages should not be considered warning signs of impending severe altitude illness due to their delayed appearance.


  • Open Access

    New Insights Into Changes in Corneal Thickness in Healthy Mountaineers During a Very-High-Altitude Climb to Mount Muztagh Ata

    by Martina Monika Bosch, Daniel Barthelmes, Tobias Michael Merz, Pascal Bruno Knecht, Frederic Truffer, Konrad E. Bloch, Michael A. Thiel, Benno L. Petrig, Alexander J. Turk, Otto D. Schoch, et al.

    Objective To investigate the effect of very high altitude and different ascent profiles on central corneal thickness (CCT). Methods Twenty-eight healthy mountaineers were randomly assigned to 2 different ascent profiles during a medical research expedition to Mount Muztagh Ata (7546 m) in western China. Group 1 was allotted a shorter acclimatization time prior to ascent to 6265 m. The main outcome measure was CCT. Secondary outcome measures were oxygen saturation (SpO2) and symptom assessments of acute mountain sickness (cerebral acute mountain sickness score). Examinations were performed at 490, 4497, 5533, and 6265 m. Results Central corneal thickness increased in both groups with increasing altitude and decreased after descent. In group 1 (with the shorter acclimatization), mean CCT increased from 537 to 572 μm. Mean CCT in group 2 increased from 534 to 563 μm (P = .048). The amount of decrease in SpO2 paralleled the increase in CCT. There was no significant decrease in visual acuity. There was a significant correlation between CCT and cerebral acute mountain sickness score when controlled for SpO2 and age. Conclusions Corneal swelling during high-altitude climbs is promoted by low SpO2. Systemic delivery of oxygen to the anterior chamber seems to play a greater role in corneal oxygenation than previously thought. Adhering to a slower ascent profile results in less corneal edema. Visual acuity in healthy corneas is not adversely affected by edema at altitudes of up to 6300 m. Individuals with more acute mountain sickness–related symptoms had thicker corneas, possibly due to their higher overall susceptibility to hypoxia.


  • Blackening of a Choroidal Hemangioma after Photodynamic Therapy

    by M. M. Bosch, H. Helbig

    Hintergrund: Die photodynamische Therapie hat sich in letzter Zeit zur Standardtherapie symptomatischer Aderhauthämangiome entwickelt. Anamnese und Befund: Ein 60-jähriger Mann wurde wegen progredienten Visusverlusts auf 0,25 am linken Auge zugewiesen. Am Fundus fand sich oberhalb der Fovea eine rötliche subretinale Prominenz mit Pigmentunregelmäßigkeiten in der Umgebung. Der Ultraschall zeigte eine hohe interne Reflektivität und eine Prominenz von 3,3 mm. Indocyaningrün- und Fluoreszein-Angiographie zeigten eine frühe Füllung großer Gefäße innerhalb des Tumors. Therapie und Verlauf: Die Läsion wurde mit photodynamischer Therapie mit Verteporphin behandelt. Zwei Tage später zeigte sich bei unverändertem Visus eine blau-schwarze Verfärbung des Tumors. Nach 2 Monaten war der Visus auf 0,5 angestiegen und im Tumorbereich zeigten Funduskopie, Echographie und Angiographie eine flache chorioatrophe Narbe mit nur leichter Pigmentierung der Ränder. Schlussfolgerungen: Aderhauthämangiome können sich kurz nach Behandlung mit photodynamischer Therapie vorübergehend dunkel verfärben. Am ehesten kann dies durch die Bildung von intravasalen Blutkoagula in den weiten, lakunenähnlichen Gefäßsystemen des Tumors bei durch photodynamische Therapie induzierter Photothrombose erklärt werden. Background: Photodynamic therapy has recently advanced to a first line treatment of symptomatic circumscribed choroidal hemangiomas. History and signs: A sixty-year-old male patient was referred with progressive visual loss in his left eye. Visual acuity measured 20/80 and fundus examination revealed a prominent red subretinal lesion superior to the fovea with adjacent pigment epithelial irregularities. Thickening of the central retina was seen on OCT imaging. Sonography revealed a dome-shaped lesion with a maximal thickness of 3.3 mm and high internal reflectivity. Combined fundus indocyanine green and fluorescein angiography showed early filling of large vessels within the tumor. Therapy and outcome: The hemangioma was treated with verteporphin photodynamic therapy. Two days after treatment, with vision unchanged, fundus examination revealed blackening of the tumor. Two months later vision increased to 20/40 and the tumor area was atrophic and bright red with a slight hyperpigmented rim. Angiography revealed the disappearance of tumor vessels and choroidal hypoperfusion in the area of treatment. Conclusions: Choroidal hemangiomas may darken initially after photodynamic therapy. This is most probably caused by large coaguli within the voluminous lacuna-like blood-filled vessel system of the hemangioma that are induced by photothrombosis.


  • Atypical manifestation of neurofibromatosis type 2 in a boy

    by M M Bosch, A Mironov, H E Killer